IL146568A0 - Hydrochloride salt of a fused heterocyclic compound and pharmaceutical compositions containing the same - Google Patents

Hydrochloride salt of a fused heterocyclic compound and pharmaceutical compositions containing the same

Info

Publication number
IL146568A0
IL146568A0 IL14656800A IL14656800A IL146568A0 IL 146568 A0 IL146568 A0 IL 146568A0 IL 14656800 A IL14656800 A IL 14656800A IL 14656800 A IL14656800 A IL 14656800A IL 146568 A0 IL146568 A0 IL 146568A0
Authority
IL
Israel
Prior art keywords
same
pharmaceutical compositions
compositions containing
hydrochloride salt
heterocyclic compound
Prior art date
Application number
IL14656800A
Other languages
English (en)
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=15340495&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL146568(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of IL146568A0 publication Critical patent/IL146568A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IL14656800A 1999-05-24 2000-05-24 Hydrochloride salt of a fused heterocyclic compound and pharmaceutical compositions containing the same IL146568A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP14351399 1999-05-24
PCT/JP2000/003325 WO2000071540A1 (fr) 1999-05-24 2000-05-24 Chlorhydrate de compose heterocyclique fusionne

Publications (1)

Publication Number Publication Date
IL146568A0 true IL146568A0 (en) 2002-07-25

Family

ID=15340495

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14656800A IL146568A0 (en) 1999-05-24 2000-05-24 Hydrochloride salt of a fused heterocyclic compound and pharmaceutical compositions containing the same

Country Status (25)

Country Link
US (1) US6706746B2 (zh)
EP (1) EP1180519B1 (zh)
KR (2) KR100748053B1 (zh)
CN (1) CN1156473C (zh)
AT (1) ATE294799T1 (zh)
AU (1) AU763731B2 (zh)
BR (1) BR0010914A (zh)
CA (1) CA2375017C (zh)
CZ (1) CZ297927B6 (zh)
DE (1) DE60019919T2 (zh)
DK (1) DK1180519T3 (zh)
ES (1) ES2240099T3 (zh)
HK (1) HK1042087B (zh)
HU (1) HU229340B1 (zh)
IL (1) IL146568A0 (zh)
MX (1) MXPA01012044A (zh)
NO (1) NO321578B1 (zh)
NZ (1) NZ515570A (zh)
PL (1) PL209389B1 (zh)
PT (1) PT1180519E (zh)
RU (1) RU2214410C2 (zh)
TR (1) TR200103353T2 (zh)
TW (1) TWI284533B (zh)
WO (1) WO2000071540A1 (zh)
ZA (1) ZA200109576B (zh)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI284533B (en) * 1999-05-24 2007-08-01 Sankyo Co Pharmaceutical composition for treating hyperglycemia, impaired glucose tolerance, diabetes complications and for improving insulin resistant
WO2002051441A1 (fr) 2000-12-26 2002-07-04 Sankyo Company, Limited Compositions medicinales contenant un diuretique et un agent renforçant la resistance a l'insuline
US6756399B2 (en) * 2001-06-29 2004-06-29 The United States Of America As Represented By The Department Of Health And Human Services Use of lipoxygenase inhibitors and PPAR ligands as anti-cancer therapeutic and intervention agents
WO2003082865A1 (fr) * 2002-04-01 2003-10-09 Sankyo Company, Limited Composition médicinale antitumorale
AU2003254795A1 (en) * 2002-08-02 2004-02-23 Sankyo Company, Limited Resorcinol derivative
US7781464B2 (en) * 2003-01-17 2010-08-24 Bexel Pharmaceuticals, Inc. Heterocyclic diphenyl ethers
US6794401B2 (en) * 2003-01-17 2004-09-21 Bexel Pharmaceuticals, Inc. Amino acid phenoxy ethers
US7521465B2 (en) * 2003-01-17 2009-04-21 Bexel Pharmaceuticals, Inc. Diphenyl ether derivatives
US7718377B2 (en) 2003-05-29 2010-05-18 Kyoto Pharmaceutical Industries, Ltd. Insulin resistance curative and method of screening the same
US7087576B2 (en) * 2003-10-07 2006-08-08 Bexel Pharmaceuticals, Inc. Dipeptide phenyl ethers
DE602004030470D1 (de) * 2003-10-24 2011-01-20 Santen Pharmaceutical Co Ltd Therapeutisches mittel für keratokonjunktive erkrankungen
EP1566202A1 (en) * 2004-02-23 2005-08-24 Sahltech I Göteborg AB Use of resistin antagonists in the treatment of rheumatoid arthritis
EP1731170A1 (en) * 2004-03-29 2006-12-13 Sankyo Company, Limited Therapeutic agent for diabetes containing insulin resistance improving agent
TW200608967A (en) 2004-07-29 2006-03-16 Sankyo Co Pharmaceutical compositions containing with diabetic agent
CN101119748A (zh) * 2004-12-13 2008-02-06 第一三共株式会社 用于治疗糖尿病的药物组合物
CA2591416A1 (en) * 2004-12-15 2006-06-22 Daiichi Sankyo Company Limited Medicinal composition containing fbpase inhibitor
TW200637856A (en) 2005-01-24 2006-11-01 Sankyo Co Process for producing thiazolidinedion compound and intermediate thereof
WO2006126673A1 (ja) * 2005-05-27 2006-11-30 Daiichi Sankyo Company, Limited 組み合わせによる糖尿病治療薬
US20080262054A1 (en) * 2005-07-08 2008-10-23 Takao Kawasaki Pharmaceutical Composition Containing Thiazolidinedione Compound
TW200738266A (en) * 2005-09-29 2007-10-16 Sankyo Co Pharmaceutical agent containing insulin resistance improving agent
EP1964575B1 (en) 2005-11-28 2015-09-23 Senju Pharmaceutical Co., Ltd. Pharmaceutical comprising ppar agonist
JP5294419B2 (ja) * 2007-04-05 2013-09-18 第一三共株式会社 縮合二環式ヘテロアリール誘導体
PT2151438E (pt) 2007-05-21 2012-11-15 Senju Pharma Co Produto farmacêutico contendo agonista de ppar
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
MX2011009244A (es) 2009-03-05 2011-09-26 Daiichi Sankyo Co Ltd Derivado de piridina.
WO2014152843A1 (en) 2013-03-14 2014-09-25 Deuterx, Llc Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
ES2831326T3 (es) 2014-01-15 2021-06-08 Poxel Sa Métodos para tratar trastornos neurológicos, metabólicos y otros mediante el uso de pioglitazona enantiopura enriquecida con deuterio
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ293016B6 (cs) 1995-06-01 2004-01-14 Sankyo Company Limited Benzimidazolové deriváty a farmaceutické prostředky s jejich obsahem
RU2158607C2 (ru) 1995-07-03 2000-11-10 Санкио Компани Лимитед Лечение артериосклероза и ксантомы
TWI284533B (en) * 1999-05-24 2007-08-01 Sankyo Co Pharmaceutical composition for treating hyperglycemia, impaired glucose tolerance, diabetes complications and for improving insulin resistant
NZ516636A (en) * 1999-07-19 2004-01-30 Sankyo Co Preventive and therapeutic agents for cancer

Also Published As

Publication number Publication date
HU229340B1 (en) 2013-11-28
NO321578B1 (no) 2006-06-06
WO2000071540A1 (fr) 2000-11-30
EP1180519A4 (en) 2002-07-10
KR20010113972A (ko) 2001-12-28
DE60019919T2 (de) 2006-02-16
PT1180519E (pt) 2005-06-30
HK1042087A1 (en) 2002-08-02
PL351650A1 (en) 2003-05-19
EP1180519B1 (en) 2005-05-04
AU4948700A (en) 2000-12-12
KR20070034112A (ko) 2007-03-27
ATE294799T1 (de) 2005-05-15
ES2240099T3 (es) 2005-10-16
US20020111373A1 (en) 2002-08-15
CZ297927B6 (cs) 2007-05-02
CZ20014182A3 (cs) 2002-04-17
PL209389B1 (pl) 2011-08-31
CN1364168A (zh) 2002-08-14
NO20015712L (no) 2001-12-20
BR0010914A (pt) 2002-02-19
CA2375017C (en) 2009-05-19
NO20015712D0 (no) 2001-11-23
TR200103353T2 (tr) 2002-04-22
TWI284533B (en) 2007-08-01
DE60019919D1 (de) 2005-06-09
CA2375017A1 (en) 2000-11-30
KR100783348B1 (ko) 2007-12-07
ZA200109576B (en) 2003-02-20
MXPA01012044A (es) 2002-05-06
EP1180519A1 (en) 2002-02-20
HUP0201334A3 (en) 2002-11-28
NZ515570A (en) 2003-11-28
HUP0201334A2 (en) 2002-10-28
AU763731B2 (en) 2003-07-31
US6706746B2 (en) 2004-03-16
CN1156473C (zh) 2004-07-07
KR100748053B1 (ko) 2007-08-09
DK1180519T3 (da) 2005-06-13
HK1042087B (zh) 2005-09-09
RU2214410C2 (ru) 2003-10-20

Similar Documents

Publication Publication Date Title
IL146568A0 (en) Hydrochloride salt of a fused heterocyclic compound and pharmaceutical compositions containing the same
EP0976748A4 (en) PYRROLIDINE DERIVATIVES HAVING PHOSPHOLIPASE A2 INHIBITING ACTIVITY
DK0698606T3 (da) Azolylaminderivat
RS22104A (en) Herbicide and safening combinations
WO2001032652A3 (en) N-substituted carbamoyloxyalkyl-azolium derivatives
AU7948900A (en) 4-oxoquinolizine antimicrobials having 2-pyridone skeletons as the partial structure
DE69818261D1 (en) Hydroxycyclopentanone
AU6117698A (en) Antiviral agents
EP1008345A4 (en) ANTI-ALLERGIC AGENTS
AU6418898A (en) Therapeutic agent for diabetes mellitus
AU6418698A (en) Antirheumatic agents
CA2349452A1 (en) Therapeutic agents for drug dependence
DE60238847D1 (de) Pyrimidinderivate enthaltendes medikament
EP0651945A4 (en) MEANS FOR PROTECTION FROM TERMITES.
AU5498098A (en) Tetrahydrofurans
EP1234576A4 (en) MEDICINE AGAINST EATING DISORDERS
EP1118327A4 (en) PREVENTIVE AND / OR THERAPEUTIC AGENTS FOR THE TREATMENT OF SINUSITIS.
EP0878475A3 (en) 5-(4-Piperidinyl)dibenzothiazepine derivatives and 5-(4-piperidinyl)dibenzoxazepine derivatives, and antiarrhythmic agents
AU653019B2 (en) New urea derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same
SI0987268T1 (en) Pharmaceutical agents containing epothilone A-N-oxide and/or epothilone B-N-oxide

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees